Novavax (NVAX) seems to be a great long term investment
Novavax (NVAX) currently trades at $14.70 and has fallen by 8.45% today. Novavax’s recent gains are mainly from their nanoparticle-based flu vaccine NanoFlu. The company reported overwhelmingly positive results on March 24 from a late-stage study of the vaccine in a head-to-head comparison against Sanofi’s market-leading flu vaccine Fluzone Quadrivalent. Some analysts think that it’s likely to generate blockbuster sales if approved.
Based on this information, investorsQ rates this stock 6 out of 10. We give it this rating based on current information written in this article. The high forecast for Novavax is $24.00 and the low is $19.00. Notably, the company’s market cap is $751.81 million with a 52 week high of $17.71 and a 52 week low of $3.54. NVAX went down $1.39 from the previous closing price of $16.10. NVAX has changed in price by +3.25 per share in the last 12 months.